N@N

CRY, ABMD, HGT, UTHR, TNP, CHSI Are Seasonally Ripe To Go Up In the Next Five Weeks

May 2, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of CRYOLIFE INC (NYSE:CRY), ABIOMED INC (NASDAQ:ABMD), HUGOTON ROYALTY TRUST (NYSE:HGT), UNITED THERAPEUTICS CORP (NASDAQ:UTHR), TSAKOS ENERGY NAVIGATION LTD (NYSE:TNP), CATALYST HEALTH SOLUTIONS IN (NASDAQ:CHSI) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Up:

     Symbol     Company                             Expected Return     Odds                    By The Following Date
     CRY        CRYOLIFE INC                        10.98%              72.22% (13 of 18)       Monday, May 2nd 2011
     ABMD       ABIOMED INC                         10.75%              65.22% (15 of 23)       Monday, May 2nd 2011
     HGT        HUGOTON ROYALTY TRUST               10.69%              83.33% (10 of 12)       Monday, May 2nd 2011
     UTHR       UNITED THERAPEUTICS CORP            10.69%              72.73% (8 of 11)        Monday, May 2nd 2011
     TNP        TSAKOS ENERGY NAVIGATION LTD        10.50%              77.78% (7 of 9)         Monday, May 2nd 2011
     CHSI       CATALYST HEALTH SOLUTIONS IN        10.28%              81.82% (9 of 11)        Wednesday, May 4th 2011

CRYOLIFE INC (NYSE:CRY) - CryoLife, Inc. engages in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries in the United States and Canada. Its CryoValve SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves. The companys CryoPatch SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract, a surgery commonly performed in children with congenital heart defects, such as tetralogy of Fallot, truncus arteriosus, and pulmonary atresia. CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch. CryoLifes BioGlue Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of vessels. BioGlue is also CE Marked in the European community and approved in Canada and Australia for use in soft tissue repair. The companys BioFoam Surgical Matrix is CE Marked in the European community for use as an adjunct in the sealing of abdominal parenchymal tissues when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. BIOGLUE Aesthetic Medical Adhesive is CE marked in the European Community for periosteal fixation following endoscopic browplasty in reconstructive plastic surgery. CryoLife also distributes HemoStase, a hemostatic agent for use in cardiac and vascular surgery, as well as in various international markets for cardiac, vascular, and general surgery. The company distributes its products through field service representatives, cardiac specialists, direct field representatives, and independent distributors. CryoLife was founded in 1984 and is headquartered in Kennesaw, Georgia.

ABIOMED INC (NASDAQ:ABMD) - ABIOMED, Inc., together with its subsidiaries, engages in the research, development, and sale of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Its products include Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, it provides AbioCor implantable replacement heart, a self-contained artificial heart for end-stage biventricular heart failure patients. Further, the company develops Intra-Aortic Balloon (IAB), an inflatable balloon inserted via a catheter into the patients circulation; iPulse intra-aortic Balloon Catheter, an intra-aortic counterpulsation device that passively unloads the left ventricle, reduces the workload of the heart and enhances cardiac output; and portable circulatory support driver for AB5000 for in-hospital and out-of-hospital patients. It sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, and internationally. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

HUGOTON ROYALTY TRUST (NYSE:HGT) - Hugoton Royalty Trust operates as an express trust in the United States. It holds a 80% net profits interests in certain natural gas producing working interest properties of XTO Energy Inc. XTO Energy Inc. engages in the production and sale of oil and gas, and holds working interests in the Hugoton area, which covers Texas, Oklahoma, and Kansas; the Anadarko Basin of western Oklahoma; and the Green River Basin located in southwestern Wyoming. Hugoton Royalty Trust was founded in 1998 and is based in Dallas, Texas.

UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and Internationally. It offers Remodulin, Tyvaso, and Adcirca (tadalafil) tablets for the treatment of pulmonary arterial hypertension (PAH); and CardioPAL SAVI and decipher cardiac monitors, and CardioPAL SAVI wireless cardiac event monitors for cardiac arrhythmias and ischemic heart disease. The companys under development products include Oral Treprostinil, which is in Phase III clinical trials for the treatment of PAH and is in Phase II clinical trials for the treatment of peripheral vascular disease; Beraprost-MR, a Phase II clinical trials product for the treatment of PAH; 3F8 MAb, a Phase II clinical trials product for neuroblastoma; Aviptadil, a Phase II clinical trials product targeting pulmonary hypertension and other pulmonary diseases; 8H9 MAb, a Phase I clinical trials product for the treatment of metastatic brain cancer; IW001, a Phase I clinical trials product that targets idiopathic pulmonary fibrosis and primary graft dysfunction; and Glycobiology Antiviral Agents, which are in pre-clinical trials for Hepatitis C and other infectious diseases. United Therapeutics Corporation also provides telemedicine monitoring services to detect cardiac arrhythmias and ischemic heart disease. The company sells its products through sales and marketing staff, specialty pharmaceutical distributors, and pharmaceutical wholesalers. It has a licensing agreements and relationships with Eli Lilly and Company; Toray Industries, Inc.; NEBU-TEC; Mondobiotech; ImmuneWorks; GlaxoSmithKline PLC; Pfizer Inc.; and Supernus Pharmaceuticals, Inc. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

TSAKOS ENERGY NAVIGATION LTD (NYSE:TNP) - Tsakos Energy Navigation Limited, together with its subsidiaries, provides seaborne crude oil, petroleum products, and liquefied natural gas (LNG) transportation services internationally. The company offers marine transportation services for national and independent oil companies and refiners under long, medium, and short-term charters. As of March 31, 2010, it operated a fleet of 46 double-hull tankers, including 3 VLCC tankers, 9 suezmax tankers, 12 aframax tankers, 7 panamax tankers, 6 handymax tankers, 8 handysize tankers, and 1 LNG carrier. The company was formerly known as MIF Limited and changed its name to Tsakos Energy Navigation Limited in July 2001. Tsakos Energy Navigation Limited was founded in 1993 and is based in Athens, Greece.

CATALYST HEALTH SOLUTIONS IN (NASDAQ:CHSI) - Catalyst Health Solutions, Inc., together with its subsidiaries, operates as a pharmacy benefit management company in the United States. The company provides its clients with plan designs, clinical programs, physician orientation programs, and member education through an electronic point-of-sale system for eligibility verification and plan design information, as well as offers access to rebate arrangements for various branded pharmaceuticals. It operates primarily under the Catalyst Rx brand name. The company provides its clients access to a contracted national network of approximately 63,000 pharmacies. Catalyst Health Solutions, Inc. serves self-insured employers, including state and local governments; managed care organizations; third-party administrators; unions; and individuals. The company was formerly known as HealthExtras, Inc. and changed its name to Catalyst Health Solutions, Inc. in October 2008. Catalyst Health Solutions, Inc. was founded in 1994 and is headquartered in Rockville, Maryland.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641